Markets | | |
Investors will be looking for clarity as Hewlett Packard Inc. (NYSE:HPQ) prepares to report second-quarter 2020 earnings on May 27, 2020. Whether or not the company hits analysts’ projections for revenue is largely irrelevant. On a year-over-year basis both sales and profit are likely to be ... Read the Full Story |
|
From Our PartnersThis little-known smart chip is crucial for the new 5G networks. And with 1 billion 5G devices coming online within 4 years... the market is estimated to be worth $12.3 TRILLION! This just-released special report reveals urgent details. | | Click here for instant access. |
|
Markets | | |
With restaurant dining rooms only just starting to come back in a lot of places—some have been open for most of a month in at least some capacity—one thing was clear: when the going gets tough, America gets take-out. And take-out pizza was a very big deal in the last month, as reported... Read the Full Story |
|
Markets | | | Shares of the enigmatic athleisure brand Under Armour (NYSE: UAA) (NYSE: UA) have been in a downtrend since peaking in July 2019 at $27.72 on the heels of its last upbeat earnings report. Management ate crow in the following quarters as they missed guidance and continued to lose credibility with shr... Read the Full Story |
|
|
Markets | | | And The Winner Is?
When it comes to the market and who wins and who doesn’t the only votes that count are dollars. Looking at the market and using percentage gain as the measure there is a clear winner when it comes to the pandemic. Up nearly 50% from its pre-correction levels, Tractor Supply... Read the Full Story |
|
Markets | | | If a stock is pretty much flat in terms of performance over the past two months, while the broader equity market as a whole has undergone an eye-watering powerful recovery, investors will be asking the uncomfortable questions. That’s the situation that Zoom Communications (NASDAQ: ZM) finds it... Read the Full Story |
|
From Our PartnersIf you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks. | | Then go here ASAP. |
|
The Early Bird Stock Of The Day BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California. | | View Today's Stock Pick |
|
